Prognostic value of EZH2, paxillin expression and DNA ploidy of breast adenocarcinoma: Correlation to pathologic predictors

Journal of B.U.ON.

Volumn 18, Issue 4, 2013, Pages 879-885

  Panousis, D ^a   Xepapadakis, G ^a   Lagoudianakis, E ^b   Karavitis, G ^b   Salemis, N ^b   Koronakis, N ^c   Patsouris, E ^d   Koronarchis, D ^a   Grosomanidis, D ^a   Chryssikos, G ^c   Ntasiou, P ^a   Kyriakidou, V ^a   Athanassiadou, A M ^d   Thanassiadou, P A ^d  

^a IASO GENERAL HOSPITAL   (Greece)

^b 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^c Veterans Administration Hospital NIMTS   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

Breast cancer biomarkers; Dna ploidy; EZH2; Paxillin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PAXILLIN; PROGESTERONE RECEPTOR; PROTEIN P53; TRANSCRIPTION FACTOR EZH2;

ANEUPLOIDY; ARTICLE; BREAST ADENOCARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HISTOGRAM; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PHENOTYPE; PREDICTIVE VALUE; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL DIFFERENTIATION; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; LOGISTIC MODELS; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PAXILLIN; PHENOTYPE; PLOIDIES; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; RISK FACTORS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84893105440     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Faration D,Bartlett J. Predictive markers in breast cancer - the future. Histopathology 2008;52:91-98. (Pubitemid 350265186)
2. Payne SJL, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer - the present Histopathology 2008;52:82-90. (Pubitemid 350265187)
3. Kesisis G, Kontovinis LF, Genatas C, Kortsaris AH. Biological markers in breast cancer:prognosis and treatment. J BUON 2010;15:447-454.
4. Walker RA Immunohistochemical markers as predictive tools for breast cancer. J Clin Pathol 2008:61:689-696. (Pubitemid 351859960)
5. Geiber RD, Gelber S. International Breast Cancer Study Group, Breast International Group. Facilitating consen-sus by examining pattem of treatment effects. Breast 2009; 18 (Suppl 3):S2-S8.
6. Molina R, Barack V, vom Dalen A et al. Tumor markers in breast cancer. European Group on Tumor Markers Recommendations. Tumor Biol 2005;26:281-293. (Pubitemid 41619458)
7. Raman J, Mongan N, Tickoo S, Boorjian S, Scherr D, Gudas L. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 2005;11:8570-8576. (Pubitemid 43005902)
8. Ding L, Kleer C. Enhancer of zeste 2 as a marker of preneoplastic progression in the breast Cancer Res 2006;66:9352-9355. (Pubitemid 44623628)
9. Sellers W, Loda M. The EZH2 polycomb transcriptional repressora marker or mover of metastatic prostate cancer? Cancer Cell 2002;2:349-350. (Pubitemid 41039099)
10. Sattler M, Pisick E, Morrison PT, Salgia R. Role of the cytoskeletal protein Paxillin in oncogenesis. Crit Rev Oncol 2000;11:63-76. (Pubitemid 30220599)
11. Turner C Molecules in focus:Paxillin. Intern J Biochem Cell Biol 1998;30:955-959.
12. Deakin NO, Turner CE. Distinct roles for Paxillin and Hic-5 in regulating breast cancer cell morphology, invasion and metastasis. Mol Biol Cell 2011;22:327-341.
13. Madan R, Smalkin M, Cocker R, Fayqd R, Oktay M. Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma. Hum Pathol 2006;37:9-15. (Pubitemid 41790497)
14. Brown MC, Turner CE. Paxillinadapting to change. Physiol Rev 2004;84:1315-1339.
15. Tavassoli FA, Daviles P. World Health Organization of Tumors. Pathology and genetics of tumors of the breast and female genital organs. Lyon, France, International Agency for Research on Cancer Press 2003.
16. Robins P, Pinder S, de Klek N. Histological grading of breast carcinomas:a study of interobserver agreement Human Pathol 1995;26:873-879.
17. American Joint Committee on Cancer. Breast. In:Greene FL (Ed):AJCC Cancer Staging Manual. New York, Springer, 2002, pp 171-180.
18. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction. Nat Rev Cancer 2006;6:107-116. (Pubitemid 43361543)
19. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ. Increased expression of the polycomb group gene EZH2 in transitional cell carcinoma of the bladder Clin Cancer Res 2005;11:8570-8576. (Pubitemid 43005902)
20. Pietersen A, Horlings H, Hauptmann M et al. EZH2 and BHI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 2008;10:R109.
21. Collett K, Eide GE, Ames J et al. Expression of enhancer of zest homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006; 12:1168-1174. (Pubitemid 43342505)
22. Raaphorst FM, Meijer CJ, Fieret E et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003;5:481-488. (Pubitemid 38045085)
23. Panousis D, Ntasiou P, Kyriakidou V et al. DNA ploidy in relationship with EZH2 expression as markers of breast carcinomas. Eur J Cancer 2010;8 (Suppl):114 (abstr).
24. Kleer C, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. PNAS 2003:100:11606-11611. (Pubitemid 37205983)
25. Zeidler M, Kleer CG. Enhancer of Zeste 2:Its links to DNA repair and breast cancer cells. J Mol Histol 2006;37:219-223. (Pubitemid 44795625)
26. Tie F, Furuyama T, Prasad-Sinha J, Jane E, Harte P. The Drosophila polycomb group proteins ESG and E(Z) are present in a complex containing the histone-binding protein p55 and the histone deacethylase RPD3. Development 2001;128:275-286. (Pubitemid 32124152)
27. Cao R, Zhang Y. The functions of E(Z)/EZH2 - mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004;14:155-164. (Pubitemid 38520143)
28. Sattler D. Role of the cytoskeletal protein Paxillin in oncogenesis. Crit Rev Oncol 2000;11:63-76.
29. Turner Ch. Paxillin interactions. J Cell Sci 2000;113:4139-4140.
30. Velasco-Velázquez M, Salinas-Jazmin N, Mendoza-Pa-tino N, Mandoki J. Reduced paxillin expression contributes to the antimetastatic effect of 4-hydroxycou-marin on B16-F10 melanoma cells. Cancer Cell Int 2008;8:2807-2868.
31. Kumar R, Guturay AE, Bournes CJ. p21 activated kinases in cancer. Nat Rev Cancer 2006;6:459-471.
32. Short SM, Yoder BJ, Tarr SM et al. The expression of the cytoskeletal focal adhesion protein Paxillin in breast cancer correlates with ER2 overexpression and may help predict response to chemotherapy:a retrospective immunohistochemical study. Breast J 2007;13:130-139.
33. Su LH, Dobenecker MW, Dickinson E al. Polycomb group protein ezh2 controls actin polymerization and cell signaling cell. Cell 2005;121:425-436. (Pubitemid 40692302)
34. Vadlamudi R, Adam L, Tseng B, Costa L, Kumar R. Transcriptional upregulation of Paxillin expression by heregulin in human breast cancer cells. Cancer Res 1999;59:2843-2846. (Pubitemid 29283121)
35. Yamaguchi R, Mazaki Y, Hirota K, Hashimoto S, Sale H. Mitosis specific serine phosphorylation and downregulation of one of the focal adhesion protein, Paxillin. Oncogene 1997;15:1753-1761. (Pubitemid 27478617)
36. D'Assoro AB, Barrett SL, Folk C et al. Amplified centrosomes in breast cancer:a potential indicator of tumor aggressiveness. Breast Cancer Res Treat 2002;75:25-34.